Company profile: Blaze Bioscience
1.1 - Company Overview
Company description
- Provider of products that assist surgeons treating cancer patients, including BLZ-100 (tozuleristide), a fluorescent imaging agent used in brain cancer surgery to help visualize tumors, and the CANVAS Imaging System, used in conjunction with BLZ-100 to detect and visualize tumors during surgery.
Products and services
- CANVAS Imaging System: Intraoperative imaging system used with BLZ-100 to detect and visualize tumors during surgery, enabling fluorescent visualization of tumor tissue for surgeons
- BLZ-100 (tozuleristide): Fluorescent imaging agent used in brain cancer surgery to help visualize tumors, delivering fluorescence during operations to aid tumor visualization by surgeons
- Cancer Surgery Assistance: Intraoperative product commercialization that assists surgeons to treat cancer patients by enabling tumor detection and visualization during surgery using fluorescent imaging agents and imaging systems
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Blaze Bioscience
PACT Pharma
HQ: United States
Website
- Description: Provider of personalized adoptive T cell therapies designed for the eradication of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PACT Pharma company profile →
Compass Therapeutics
HQ: United States
Website
- Description: Provider of immune system–targeting therapeutics and antibody engineering platforms. Pipeline: CTX-009, a DLL4/VEGF-A bispecific showing benefit in colorectal and gastric cancers; CTX-471, a CD137 agonist for melanoma with U.S. studies planned H2 2024; and CTX-8371, a PD-1/PD-L1 bispecific in preclinical development for solid tumors. Platforms: StitchMabs for bispecifics, common light chain discovery, and human display for antibody tuning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compass Therapeutics company profile →
Turning Point Therapeutics
HQ: United States
Website
- Description: Provider of structure-based drug discovery and development of precision medicines for cancer and other diseases, focusing on novel chemical identities for established oncogene drivers with secondary resistant mutations and newly identified disease-driven targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turning Point Therapeutics company profile →
Symphogen
HQ: Denmark
Website
- Description: Provider of recombinant polyclonal antibody drugs and platforms for disease treatment and prevention. Offers Symplex PCR cloning for antigen-specific antibodies, an antibody discovery and research platform focused on oncology and immuno-oncology, and CMC processes for manufacturing. Pipeline includes Sym013 (pan-HER antibody mixture) and Sym021 (anti-PD-1) with combinations Sym022 (anti-LAG-3) and Sym023 (anti-TIM-3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Symphogen company profile →
Oncimmune
HQ: United Kingdom
Website
- Description: Provider of proprietary autoantibody assay technologies for early cancer detection, offering ImmunoINSIGHTS analytical platform to discover and profile autoantibody biomarkers for disease characterization, patient stratification, and response prediction; biomarker discovery services; customizable targeted panels and arrays for immuno-oncology and autoimmune diseases; and bioinformatics and data science with multiomics integration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Blaze Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Blaze Bioscience
2.2 - Growth funds investing in similar companies to Blaze Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Blaze Bioscience
4.2 - Public trading comparable groups for Blaze Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →